Ianalumab (FUT8-KO)
Based on 1 Customer Validation
Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia.
For research use only. We do not sell to patients.
- Purity: 99.85%
- Molecular Weight:146.44 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
TNFRSF13C/BAFFR/CD268
Ianalumab (FUT8-KO) (10 μg/mL) blocks the activation of the alternative NF-κB pathway in BAFF-mediated primary CLL B cells and primary CLL B cells treated with Ibrutinib (HY-10997) by inhibiting p100 degradation and p52 nuclear translocation[2].
Ianalumab (FUT8-KO) (0.1-10 μg/mL) induces higher IFN-γ levels in primary CLL NK cells than Obinutuzumab (HY-P9910) at a concentration of 10 μg/mL[2].
Ianalumab (FUT8-KO) induces TNF-α production in primary monocytes and monocyte-derived macrophages from patients with chronic lymphocytic leukemia (CLL)[2].
Ianalumab (FUT8-KO) induces antibody-dependent cellular phagocytosis of primary chronic lymphocytic leukemia (CLL) B cells by monocyte-derived macrophages, at levels comparable to those of clinically relevant CD20-targeting antibodies[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ianalumab (FUT8-KO) (10 mg/kg; Retro-orbital injection; once weekly; up to 6 weeks) improves survival and reduces chronic lymphocytic leukemia burden in SCID mice engrafted with leukemic Eμ-TCL1 splenocytes compared to ibrutinib monotherapy[2].
Combination treatment withIanalumab (FUT8-KO) (10 mg/kg; Retro-orbital injection; once weekly; up to 6 weeks) and ibrutinib significantly improves survival and reduces chronic lymphocytic leukemia burden in SCID mice engrafted with leukemic Eμ-TCL1 splenocytes compared to either monotherapy alone[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Eμ-TCL1 transgenic mice (C57BL/6 background; spontaneous endogenous CLL development)[2]
-
Dosage:100 mg/kg
-
Administration:Retro-orbital injection; once weekly; 2 weeks
-
Result:Reduced circulating leukemic cell counts from a pre-treatment mean of ~3.6×107 cells/mL to 2.7×106 cells/mL 24 hours post-treatment.
Reduced the mean percentage of circulating leukemic lymphocytes from 78.1% to 5.2%.
Maintained low leukemic counts up to 80 days post-treatment.
-
Animal Model:C.B17 severe combined immunodeficiency (SCID) mice (adoptive transfer of splenocytes from leukemic Eμ-TCL1 mice)[2]
-
Dosage:10 mg/kg
-
Administration:Retro-orbital injection; once weekly; up to 6 weeks
-
Result:Extended median survival to 115 days, which was significantly longer than the median survival of mice treated with ibrutinib alone.
Reduced peripheral blood leukemic burden (white blood cell counts and CD5+ CD19+ lymphocyte percentages) compared to vehicle and ibrutinib monotherapy.
Reduced splenic/bone marrow disease burden compared to vehicle and ibrutinib monotherapy.\nExtended median survival to 170 days, which was significantly longer than the median survival of mice treated with VAY-736 alone and ibrutinib alone.
Eliminated peripheral blood leukemia through week 10 compared to monotherapy groups.
Reduced splenic and bone marrow disease burden compared to monotherapy groups.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized Human BAFFR/TNFRSF13C, Fc tag can bind Ianalumab (FUT8-KO). The EC50 for this effect is 4.477 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 146.44 kDa
-
Color Colorless to light yellow
-
SMILES
[Ianalumab (FUT8-KO)]
-
Synonyms
VAY-736 (FUT8-KO)
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Dörner T, et al. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019;78(5):641-647. [Content Brief]
[2]. McWilliams EM, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019;3(3):447-460. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ianalumab (FUT8-KO) Related Classifications
HY-P99653A Related Classifications
Powered by Bioz